Nootropics(/n.əˈtrpɪks/noh-ə-TROHP-iksor/n.əˈtrɒpɪks/noh-ə-TROP-iks;[1]but not/njˈtrpɪks/new-TROHP-iksor/njˈtrɒpɪks/new-TROP-iks,[1]which are common mispronunciations[citation needed]), colloquiallybrain supplements,smart drugsandcognitive enhancers,are natural, semisynthetic or syntheticcompoundswhich purportedly improvecognitive functions,such asexecutive functions,attentionormemory.

Illustration of Coffea arabica plant and seeds
Caffeinefrom theCoffea arabicaplant is the world's most consumed nootropic.

While commonly in the form ofdietary supplements,nutraceuticalsorenergy drinks,[2]some nootropic compounds areprescriptionand non-prescription drugs in various countries.

In the United States, nootropics are commonly advertised with unproven claims of effectiveness for improving cognition. TheFederal Trade CommissionandFDAhave warned manufacturers and consumers about possibleadvertising fraudandmarketing scamsconcerning nootropic supplements.[3][4]

History of term

edit

The termnootropicis derived fromAncient Greekνόος(nóos)'mind' andτροπή(tropḗ)'turning'.[1][5][6]

The first documented use of "nootropic" in reference to substances purported to increase cognitive functions was byCorneliu E. Giurgeain 1972.[5][6][7]When researching a new compound, Giurgea found a spectrum of effects that did not align with any psychotropic drug category, leading to his proposal of a new category and the concept of the term nootropic.[6]

Giurgea stated that nootropic drugs should have the following characteristics:

  1. They should enhancelearningandmemory.
  2. They should enhance the resistance of learned behaviors or memories to conditions which tend to disrupt them (e.g.electroconvulsive shock,hypoxia).
  3. They should protect the brain against various physical or chemical injuries.
  4. They should increase the efficacy of the toniccorticalcontrol mechanisms.
  5. They should lack the usual pharmacology of otherpsychotropicdrugs (e.g.sedation,motor stimulation) and possess fewadverse effectsand lowtoxicity.

However, there is no globally accepted or clinical definition of a nootropic. Most compounds described as nootropic do not correspond to Giurgea's characteristics.[7]

Unproven marketing claims

edit

In the United States, nootropics are commonly advertised with unproven claims of effectiveness for improving cognition. Manufacturers' marketing claims for dietary supplements are usually not formally tested and verified by independent entities.[8]In 2019, the US FDA andFTCwarnedmanufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplement products.[3][4][9][10]The FDA and FTC stated that some nootropic products had not beenapprovedas a prescription drug effective for any medical purpose, were not proven to be safe, and were illegally marketed in the United States under violation of theFederal Food, Drug, and Cosmetic Act.[3][4]

In 2018 in the United States, some nootropic supplements were identified as having misleading ingredients and illegal marketing.[11][12]In 2019, the FDA and FTC warned manufacturers and consumers about possible advertising fraud and marketing scams concerning nootropic supplements.[3][4]

Over the years 2010 to 2019, the FDA warned numerous supplement manufacturers about the illegal status of their products as unapproved drugs with no proven safety or efficacy at the doses listed on the products, together with misleading marketing.[3][4][9][10][13][14]

Availability and prevalence

edit

In 2008, stimulants, such as caffeine, were the most commonly used nootropic agent.[15]In 2016, theAmerican Medical Associationadopted a policy to discourage prescriptions of nootropics for healthy people, on the basis that the cognitive effects appear to be highly variable among individuals, are dose-dependent, and limited or modest at best.[16]Piracetam,noopeptandmeclofenoxatehave been sold as dietary supplements.[2][17][18]

Adverse effects

edit

The main concern withpharmaceutical drugsand dietary supplements areadverse effects.Long-term safety evidence is typically unavailable for many nootropic compounds.Racetams,piracetam and other compounds that are structurally related to piracetam, have few serious adverse effects and lowtoxicity,but there is little evidence that they enhance cognition in people having no cognitive impairments.[19]

In the United States, dietary supplements may be marketed if the manufacturer can show that the supplement isgenerally recognized as safe,and if the manufacturer does not make any claims about using the supplement to treat or prevent any disease or condition; supplements that contain drugs or advertisehealth claimsare illegal under US law.[20]

Types

edit

Central nervous system stimulants

edit

Systematic reviewsandmeta-analysesofclinical researchusing low doses of certaincentral nervous systemstimulants found that these drugs may enhance cognition in healthy people.[21][22][23]In particular, the classes of stimulants that demonstrate possible cognition-enhancing effects in humans have evidencein vitroasdirect agonistsorindirect agonistsofdopamine receptor D1oradrenoceptor A2.[21][22][24][25]Relatively high doses of stimulants cause cognitive deficits.[24][25]

  • Amphetamine– systematic reviews and meta-analyses report that low-dose amphetamine may improve cognitive functions (e.g.,inhibitory control,episodic memory,working memory,and aspects ofattention) in healthy people and in individuals withADHD.[21][22][23][25]A 2014 systematic review noted that low doses of amphetamine also improvememory consolidation,in turn leading to improvedrecall of informationin non-ADHD youth.[23]It also improvestask saliency(motivation to perform a task) and performance on tedious tasks that required a high degree of effort.[22][24][25]
  • Caffeine– a meta-analysis found an increase in alertness and attentional performance.[26][24]
  • Eugeroics(armodafinilandmodafinil) – are classified as "wakefulness-promoting agents"; modafinil may increase alertness, particularly insleep-deprivedindividuals, and may improve reasoning and problem solving in non-ADHD youth.[23]In a systematic review of small, preliminary studies where the effects of modafinil were examined, when simple psychometric assessments were considered, modafinil intake enhanced executive function.[27]Modafinil does not improve mood or motivation in sleep-deprived or non-sleep deprived individuals.[28]
  • Methylphenidate– abenzylpiperidinederivative that may improveworking memory,episodic memory,andinhibitory control,aspects ofattention,and planning latency in healthy people.[21][23]It also may improve task saliency and performance on tedious tasks.[25]At above optimal doses, methylphenidate has off–target effects that decrease learning.[29]
  • Nicotine– has been associated with improved alertness, attention, memory, and motor performance, according to ameta-analysis.[30]However, a 2020 systematic review raised concerns about potential conflicts of interest, noting industry funding in many studies and inconsistent results regarding nicotine's cognitive effects. This review found that over half of the studies published after 2010 had tobacco industry affiliations, often undisclosed.[31]

Racetams

edit

Racetams, such as piracetam,oxiracetam,phenylpiracetam,andaniracetam,are often marketed as cognitive enhancers and soldover the counter.[2][17]A 2019 study found that piracetam supplements sold in the United States were inaccurately labeled.[17]Racetams are often referred to as nootropics, but this property is not well established in humans, and nootropics are not consistently found in all racetams.[32]The racetams have poorly understoodmechanisms,although piracetam and aniracetam are known to act aspositive allosteric modulatorsofAMPA receptorsand appear to modulatecholinergicsystems.[33]

According to the FDA,

Piracetam is not avitamin,mineral,amino acid,herb or otherbotanical,or dietary substance for use by humans to supplement the diet by increasing the total dietary intake. Further, piracetam is not a concentrate, metabolite, constituent, extract or combination of any such dietary ingredient. [...] Accordingly, these products are drugs, under section 201(g)(1)(C) of the Act, 21 U.S.C. § 321(g)(1)(C), because they are not foods and they are intended to affect the structure or any function of the body. Moreover, these products are new drugs as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.[14]

Cholinergics

edit

Some supposed nootropic substances are compounds and analogues ofcholine,aprecursorof acetylcholine (aneurotransmitter) andphosphatidylcholine(a structural component ofcell membranes).

  • Alpha-GPC– L- Alpha glycerylphosphorylcholine has been studied only in the context of cognitive performance alongside other substances such as caffeine.[34]
  • Choline bitartrate– Choline bitartrate is atartaric acidsalt containing choline (41% choline by molecular weight). One meta-analysis found choline bitartrate to be ineffective at improving any measure of cognitive performance.[35]
  • Citicoline– Compound consisting of choline andcytidine.A meta-analysis found that it may be effective for improving memory and learning in older people with mild cognitive decline, and in people recovering from a stroke.[36][37]

Herbs

edit
  • Centella asiatica– A 2017 meta-analysis showed no significant improvement in cognitive function.[38]Clinical efficacy and safety have not been scientifically confirmed for this herb.[39]
  • Ginkgo biloba– An extract ofGinkgo bilobaleaf is marketed indietary supplementform with claims it can enhancecognitive functionin people without known cognitive problems, although there is no high-quality evidence to support such effects on memory or attention in healthy people.[40][41]
  • Panax ginseng– ACochrane reviewfound possible "improvement of some aspects of cognitive function, behavior and quality of life", but concluded that "there is a lack of convincing evidence to show a cognitive enhancing effect ofPanax ginsengin healthy participants and no high quality evidence about its efficacy in patients with dementia. "[42]

Nutrients and dietary supplements

edit

See also

edit

References

edit
  1. ^abc"Shubham".Oxford English Dictionary.2024.RetrievedJanuary 14,2024.
  2. ^abcCohen PA, Avula B, Wang YH, Zakharevich I, Khan I (June 2021)."Five Unapproved Drugs Found in Cognitive Enhancement Supplements".Neurology. Clinical Practice.11(3): e303–e307.doi:10.1212/CPJ.0000000000000960.PMC8382366.PMID34484905.
  3. ^abcde"FTC and FDA Send Warning Letters to Companies Selling Dietary Supplements Claiming to Treat Alzheimer's Disease and Remediate or Cure Other Serious Illnesses Such as Parkinson's, Heart Disease, and Cancer".US Food and Drug Administration, US Federal Trade Commission. February 11, 2019.RetrievedMay 11,2019.
  4. ^abcde"Health fraud scams: Unproven Alzheimer's disease products".US Food and Drug Administration. December 22, 2018.RetrievedMay 11,2019.
  5. ^abGiurgea C (1972). "[Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology]".Actualites Pharmacologiques(in French).25:115–156.PMID4541214.
  6. ^abcGiurgea C, Salama M (January 1, 1977). "Nootropic drugs".Progress in Neuro-Psychopharmacology.1(3): 235–247.doi:10.1016/0364-7722(77)90046-7.The term "nootropic" (noos = mind; tropein = towards) was proposed by us (Giurgea, 1972,1973) to designate psychotropic drugs
  7. ^abMalík M, Tlustoš P (August 2022)."Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs".Nutrients.14(16): 3367.doi:10.3390/nu14163367.PMC9415189.PMID36014874.
  8. ^"Dietary Supplements: What You Need to Know".US Food and Drug Administration.RetrievedFebruary 14,2015.
  9. ^abCorrell Jr WA (February 5, 2019)."FDA Warning Letter: Peak Nootropics LLC aka Advanced Nootropics".Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration.RetrievedMay 11,2019.
  10. ^abCorrell Jr WA (February 5, 2019)."FDA Warning Letter: TEK Naturals".Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration.RetrievedMay 11,2019.
  11. ^Schultz H (May 17, 2018)."Some shady ingredients find home in nootropics category".NutraIngredients-USA, William Reed Business Media Ltd.RetrievedMay 11,2019.
  12. ^Heid M (January 23, 2019)."Nootropics, or 'Smart Drugs,' Are Gaining Popularity. But Should You Take Them?".Time.RetrievedMay 12,2019.
  13. ^Singleton ER (January 7, 2010)."FDA Warning Letter: Cerebral Health LLC".Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration. Archived fromthe originalon January 12, 2017.RetrievedMay 12,2019.
  14. ^abJohn Gridley (August 30, 2010)."FDA Warning Letter: Unlimited Nutrition".Office of Compliance, Center for Food Safety and Applied Nutrition, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration. Archived fromthe originalon January 12, 2017.RetrievedApril 5,2016.
  15. ^Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ (December 2008)."Towards responsible use of cognitive-enhancing drugs by the healthy"(PDF).Nature.456(7223): 702–705.Bibcode:2008Natur.456..702G.doi:10.1038/456702a.OCLC01586310.PMID19060880.S2CID3598099.
  16. ^"AMA confronts the rise of nootropics".American Medical Association. June 14, 2016.RetrievedMay 12,2019.
  17. ^abcCohen PA, Zakharevich I, Gerona R (March 2020)."Presence of Piracetam in Cognitive Enhancement Dietary Supplements".JAMA Internal Medicine.180(3): 458–459.doi:10.1001/jamainternmed.2019.5507.PMC6902196.PMID31764936.
  18. ^Cohen PA, Avula B, Khan I (October 2022). "The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements".Clinical Toxicology.60(10): 1156–1158.doi:10.1080/15563650.2022.2109485.PMID35959800.S2CID251516603.
  19. ^Malykh AG, Sadaie MR (February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders".Drugs.70(3): 287–312.doi:10.2165/11319230-000000000-00000.PMID20166767.S2CID12176745.
  20. ^Goldman P (October 2001). "Herbal medicines today and the roots of modern pharmacology".Annals of Internal Medicine.135(8 Pt 1): 594–600.doi:10.7326/0003-4819-135-8_Part_1-200110160-00010.PMID11601931.S2CID35766876.
  21. ^abcdSpencer RC, Devilbiss DM, Berridge CW (June 2015)."The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex".Biological Psychiatry.77(11): 940–950.doi:10.1016/j.biopsych.2014.09.013.PMC4377121.PMID25499957.
  22. ^abcdIlieva IP, Hook CJ, Farah MJ (June 2015)."Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis".Journal of Cognitive Neuroscience.27(6): 1069–1089.doi:10.1162/jocn_a_00776.PMID25591060.S2CID15788121.
  23. ^abcdeBagot KS, Kaminer Y (April 2014)."Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review".Addiction.109(4): 547–557.doi:10.1111/add.12460.PMC4471173.PMID24749160.
  24. ^abcdWood S, Sage JR, Shuman T, Anagnostaras SG (January 2014)."Psychostimulants and cognition: a continuum of behavioral and cognitive activation".Pharmacological Reviews.66(1): 193–221.doi:10.1124/pr.112.007054.PMC3880463.PMID24344115.
  25. ^abcdeMalenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). "14: Higher Cognitive Function and Behavioral Control".Molecular Neuropharmacology: A Foundation for Clinical Neuroscience(3 ed.). New York: McGraw-Hill Medical.ISBN9780071827706.
  26. ^Camfield DA, Stough C, Farrimond J, Scholey AB (August 2014)."Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis".Nutrition Reviews.72(8): 507–522.doi:10.1111/nure.12120.PMID24946991.
  27. ^Battleday RM, Brem AK (November 2015). "Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review".European Neuropsychopharmacology.25(11): 1865–1881.doi:10.1016/j.euroneuro.2015.07.028.PMID26381811.S2CID23319688.
  28. ^Mohamed AD (2017)."Does modafinil improve cognitive functioning in healthy individuals?".In ter Meulen R, Hall W, Mohammed AD (eds.).Rethinking Cognitive Enhancement.Oxford University Press. p. 116.ISBN9780198727392.
  29. ^Urban KR, Gao WJ (2014)."Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain".Frontiers in Systems Neuroscience.8:38.doi:10.3389/fnsys.2014.00038.PMC4026746.PMID24860437.
  30. ^Heishman SJ, Kleykamp BA, Singleton EG (July 2010)."Meta-analysis of the acute effects of nicotine and smoking on human performance".Psychopharmacology.210(4): 453–469.doi:10.1007/s00213-010-1848-1.PMC3151730.PMID20414766.
  31. ^Pasetes SV, Ling PM, Apollonio DE (January 2020)."Cognitive performance effects of nicotine and industry affiliation: a systematic review".Substance Abuse: Research and Treatment.14:117822182092654.doi:10.1177/1178221820926545.ISSN1178-2218.PMC7271274.PMID32547048.
  32. ^Malenka RC, Nestler EJ, Hyman SE (2009). Sydor A, Brown RY (eds.).Molecular Neuropharmacology: A Foundation for Clinical Neuroscience(2 ed.). New York: McGraw-Hill Medical. p. 454.ISBN9780071481274.
  33. ^Gualtieri F, Manetti D, Romanelli MN, Ghelardini C (2002). "Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs".Current Pharmaceutical Design.8(2): 125–138.doi:10.2174/1381612023396582.PMID11812254.
  34. ^Parker AG, Byars A, Purpura M, Jäger R (September 21, 2015)."The effects of Alpha -glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility".Journal of the International Society of Sports Nutrition.12(Suppl 1): P41.doi:10.1186/1550-2783-12-S1-P41.ISSN1550-2783.PMC4595381.
  35. ^Lippelt DP, van der Kint S, van Herk K, Naber M (June 24, 2016)."No Acute Effects of Choline Bitartrate Food Supplements on Memory in Healthy, Young, Human Adults".PLOS ONE.11(6): e0157714.Bibcode:2016PLoSO..1157714L.doi:10.1371/journal.pone.0157714.PMC4920398.PMID27341028.
  36. ^Fioravanti M, Buckley AE (September 2006)."Citicoline (Cognizin) in the treatment of cognitive impairment".Clinical Interventions in Aging.1(3): 247–251.doi:10.2147/ciia.2006.1.3.247.PMC2695184.PMID18046877.
  37. ^Franco-Maside A, Caamaño J, Gómez MJ, Cacabelos R (October 1994). "Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer's disease".Methods and Findings in Experimental and Clinical Pharmacology.16(8): 597–607.PMID7760585.
  38. ^Puttarak P, Dilokthornsakul P, Saokaew S, Dhippayom T, Kongkaew C, Sruamsiri R, Chuthaputti A, Chaiyakunapruk N (September 2017)."Effects of Centella asiatica (L.) Urb. on cognitive function and mood related outcomes: A Systematic Review and Meta-analysis".Scientific Reports.7(1): 10646.Bibcode:2017NatSR...710646P.doi:10.1038/s41598-017-09823-9.PMC5587720.PMID28878245.
  39. ^"Gotu kola".Drugs. January 23, 2023.RetrievedSeptember 21,2023.
  40. ^Laws KR, Sweetnam H, Kondel TK (November 2012). "Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis".Human Psychopharmacology.27(6): 527–533.doi:10.1002/hup.2259.PMID23001963.S2CID6307491.
  41. ^"Ginkgo".National Center for Complementary and Integrative Health, US National Institutes of Health. September 2016.RetrievedJuly 9,2018.
  42. ^Geng J, Dong J, Ni H, Lee MS, Wu T, Jiang K, Wang G, Zhou AL, Malouf R (December 2010). "Ginseng for cognition".The Cochrane Database of Systematic Reviews(12): CD007769.doi:10.1002/14651858.CD007769.pub2.PMID21154383.
  43. ^abcdeForbes SC, Holroyd-Leduc JM, Poulin MJ, Hogan DB (December 2015)."Effect of Nutrients, Dietary Supplements and Vitamins on Cognition: a Systematic Review and Meta-Analysis of Randomized Controlled Trials".Canadian Geriatrics Journal.18(4): 231–245.doi:10.5770/cgj.18.189.PMC4696451.PMID26740832.
  44. ^Gillies D, Leach MJ, Perez Algorta G (April 2023)."Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents".The Cochrane Database of Systematic Reviews.2023(4): CD007986.doi:10.1002/14651858.CD007986.pub3.PMC10103546.PMID37058600.
  45. ^Tan ML, Ho JJ, Teh KH (December 2012). Tan ML (ed.). "Polyunsaturated fatty acids (PUFAs) for children with specific learning disorders".The Cochrane Database of Systematic Reviews.12:CD009398.doi:10.1002/14651858.CD009398.pub2.PMID23235675.
  46. ^Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P (July 2015)."Omega-3 polyunsaturated fatty acid supplementation and cognition: A systematic review and meta-analysis".Journal of Psychopharmacology.29(7): 753–763.doi:10.1177/0269881115587958.PMID26040902.S2CID358375.
edit